“You're never really off time”: Healthcare providers' interpretations of optimal timing for HPV vaccination  by Henrikson, Nora B. et al.
Preventive Medicine Reports 4 (2016) 94–97
Contents lists available at ScienceDirect
Preventive Medicine Reports
j ourna l homepage: ht tp : / /ees.e lsev ie r .com/pmedrShort Communication
“You're never really off time”: Healthcare providers' interpretations of optimal timing
for HPV vaccination
Nora B. Henrikson a,b,⁎, Leah Tuzzio a, Melissa B. Gilkey c, Annie-Laurie McRee d
a Group Health Research Institute, 1730 Minor Ave, Suite 1600, Seattle, WA 98101, USA
b School of Public Health, University of Washington, Seattle, WA, USA
c Department of Population Medicine, Harvard Medical School & Harvard Pilgrim Health Care Institute, 133 Brookline Ave, Boston, MA 02215, USA
d Division of General Pediatrics and Adolescent Health, University of Minnesota, 717 Delaware St SE, Minneapolis, MN 55414, USAAbbreviation: HPV, human papillomavirus.
⁎ Corresponding author at: Group Health Research In
1600, Seattle, WA 98101, USA.
E-mail address: henrikson.n@ghc.org (N.B. Henrikson)
http://dx.doi.org/10.1016/j.pmedr.2016.05.002
2211-3355/© 2016 The Authors. Published by Elsevier Inca b s t r a c ta r t i c l e i n f oArticle history:
Received 24 December 2015
Received in revised 2 May 2016
Accepted 16 May 2016
Available online 16 May 2016Healthcare providers have a strong inﬂuence on human papillomavirus (HPV) vaccination decisions, yet they
often fail to recommend the vaccine to the 11- and 12-year-olds who are targeted by practice guidelines. We
sought to understand how providers interpret and value age-based guidelines.
We conducted a secondary analysis of data from two qualitative studies of healthcare providers' HPV vaccination
attitudes and practices. Participants were physicians, nurse practitioners, and physician assistants in Minnesota
(n = 27) and in Washington (n = 17) interviewed in 2012 and 2014 respectively. Verbatim transcripts from
each study were analyzed independently using content analysis, and collective ﬁndings were then jointly ana-
lyzed. The research team worked via consensus to derive codes and describe representative themes.
A high proportion of providers reported either a lack of concern aboutHPV vaccine completion, or concern begin-
ning several years past the recommended target age. Many providers perceived a gradient of HPV vaccination
timeliness ranging fromage 12 to 26. Instead of age-based recommendations, providers timed recommendations
based on perceptions of access to care and patient risk. They often offered “gentle” recommendations and de-
ferred vaccination discussions as a tool to building trust with families.
Interventions aimed at helping providers deliver effective recommendations for timely HPV vaccination are
needed. Our ﬁndings suggest that changing the norm of provider culture to one in which “catch-up” schedules
are seen as a suboptimal way to achieve vaccine uptake may be an important goal.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Human papillomavirus (HPV) vaccination
Patient-provider communication1. Introduction
Rates of HPV vaccine initiation and completion are well below na-
tional goals (Stokley et al., 2014). The Centers for Disease Control and
Prevention's (CDC) recommended schedule is for routine HPV vaccina-
tion at ages 11 and 12, with catch-up vaccination up to age 26 for fe-
males and age 21 for males (Markowitz et al., 2014). A healthcare
provider's recommendation is the strongest known predictor of initia-
tion and completion the 3-dose HPV vaccine series (Dorell et al., 2012;
Kessels et al., 2012; Reiter et al., 2013a). However, many adolescents
do not receive a recommendation (Reiter et al., 2013b; Vadaparampil
et al., 2011). Previous research suggests that providers may be hesitant
to discuss HPV vaccinationwith parents of young adolescents andmore
often deliver recommendations to older adolescents than to those ages
11 to 12,(Vadaparampil et al., 2011; McRee et al., 2014) suggesting thatstitute, 1730 Minor Ave. Suite
.
. This is an open access article underproviders may not be interpreting guidelines as intended.We sought to
understand how providers interpret and value age-based guidelines in
their clinical practice, with attention to the timing of vaccination during
the target age range for routine recommendation.
2. Material and methods
2.1. Data
We used data from two qualitative studies of HPV vaccination atti-
tudes and practices among clinicians who provide preventive care, in-
cluding vaccinations, to adolescents.
Data for study 1 (Minnesota) were collected through semi-
structured, in-depth, face-to-face interviews with health care providers
(n = 27) who saw adolescent patients in Minneapolis and St. Paul, MN
between July and September 2012. We employed a purposive sampling
strategy to ensure a diversity of perspectives based on clinician training,
specialty, and clinic setting. We enrolled new participants and con-
ducted interviews,meeting regularly to discuss ﬁndings, until we deter-
mined that interviews were no longer yielding new informationthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Participant characteristics, Minnesota (2012) and Washington (2015), USA.
Minnesota
sample (n = 27)
Washington sample
(n = 17)
n (%) n (%)
Sex
Female 22 (81) 11 (65)
Male 5 (19) 6 (35)
Professiona
MD 17 (63) 17 (100)
NP/PA 10 (37) –
Specialty
Pediatrics 13 (48) 13 (76)
Family medicine 14 (52) 4 (24)
Practice afﬁliationb
Public clinic/community health center 13 (48) –
Hospital/medical center 2 (7) –
Practice network/HMO 5 (19) 100 (100)
Private, independent practice 7 (26) –
Minnesota
sample (n = 27)
Washington sample
(n = 17)
mean (range) mean (range)
No. years post-trainingc 7 (2–49) 30 (9–42)
a Only MDs were interviewed for the WA sample.
b All clinicians in the WA sample were part of a single practice network.
c Post residency/training for MN sample, post medical school graduation for WA
sample.
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questions to explore providers' HPV vaccine recommendation practices
for 11–14year old patients: “Howdoyou counsel patients and their par-
ents about HPV vaccine?”. This item included a probe asking how
strongly providers recommend the vaccine, and “How do you discuss
the vaccine with a parent who might be hesitant to get their son or
daughter vaccinated against HPV?” Participants received $40 at the
completion of the interview. Study protocols were approved by the In-
stitutional Review Board at the University of Minnesota.
Data for study 2 (Washington)were collected duringNovember and
December 2014 through individual telephone interviews with a purpo-
sive sample of primary care physicians (n= 17) in Group Health Coop-
erative, a regional integrated care system in Washington State that
serves almost 600,000 people. We conducted interviews and reviewed
the transcripts to discuss ﬁndings until we reached saturation. To ex-
plore providers' perspectives on vaccination timeliness, we asked pro-
viders: “At what point do you worry that your patients won't
complete the HPV vaccine series?” Physicians did not receive any com-
pensation. The Group Health Research Institute Institutional Review
Board determined that this study was not human subject research.
2.2. Analysis
The two datasets remained independent. Interviews fromboth stud-
ies were transcribed verbatim. Transcripts were analyzed using content
analysis methods, searching for speciﬁc references to HPV vaccine rec-
ommendation practices and how the vaccination schedule age-based
recommendations were being interpreted in clinician practice. In the
Minnesota dataset, two investigators (ALM, MBG) analyzed all the in-
terviews with a targeted search. In the Washington dataset, two inves-
tigators (NBH, LT) analyzed the answers to the “when do you worry”
question and also the remainder of the interview text. We then jointly
analyzed the collective ﬁndings from both datasets through a series of
analysis meetings, working via consensus to put the relevant results
into meaningful descriptive categories. We identiﬁed exemplar quotes
from each dataset.
3. Results
We analyzed interviews from a total of 44 providers (Table 1). For
theMinnesota study, we approached 38 providers and conducted inter-
views with 27 (71%). The sample included 17 physicians and 10 nurse
practitioners or physician assistants. Eighty-one percent (81%) were fe-
male, about half (48%) reported a pediatric specialty, and themost com-
mon practice setting was public clinic or community health center
(48%). About half (48%) of providers reported spending at least 10 h
per week providing clinical care to male or female adolescent patients.
In the Washington study we approached 31 physicians and con-
ducted interviews with 17 (55%). The sample was 65% female and
three quarters (76%) pediatricians. The mean time since medical school
graduation was 30 years. Providers reported seeing between 2 and 60
adolescents per week.
3.1. Providers described a gradient of on-time HPV vaccination ranging
from age 12 to age 26
The overarching theme in both samples was a perceived age gradi-
ent, not just for allowable vaccination, but for timely vaccination. Pro-
viders in neither sample interpreted age 12 as a hard rule for on-time
HPV vaccination. Rather, increasing age was commonly described as a
gradually pressing prompt toward recommendation of the vaccine. In
the Washington sample, the only sample in which the question was
asked directly, 13 of 17 providers (76%) reported that they do not
worry about HPV vaccine series completion by age 12. Of these, nine
(53%) reported not worrying at all and 4 (24%) reported not worrying
until age 16 or later. Age 16 was the earliest age at which providersreported feeling urgency to initiate or complete the series, and some re-
ported not feeling urgency until patients' 20s (“you're supposed to be
able to ﬁnish it anytime, I think”). In theMinnesota sample several pro-
viders referred to a similarly extended window in which their patients
were eligible for HPV vaccine, suggesting a common perception that
“you are never really off time” for the vaccine. Exemplar quotes are pre-
sented in Table 2.
3.2. Providers reﬁned their recommendations based on their perceptions of
patients' access to care and sexual risk
Instead of following a solely age-based recommendation, providers
reported an individualized approach to timing their vaccine recommen-
dations inwhich increasing agemight be but one factor.Many providers
reported either relaxed approach earlier in adolescence (“I know I'll see
them again”) or a more urgent recommendation as their patients ap-
proach transition out of high school or pediatric care as they may be
“less likely to get [all of the shots]” once in college. Further, several pro-
viders in both samples reﬂected on their judgments of individual pa-
tients' risk of sexual debut or of the sexual risk of their “patient
population” more broadly, and a feeling that continued sexual naiveté
justiﬁed delayed vaccination.
3.3. Providers perceived that a “gentler” recommendation honors parent
preferences and builds long-term trust
As a logical progression from a perception of the “true” window for
HPV vaccination extending to age 26, providers often reported deferring
discussions or recommendations until subsequent visits, giving parents
“permission to delay.”One provider reported “I would rather have them
come in andhave the discussion than not have them come in at all.” Sev-
eral providers viewed the delay of HPV vaccine discussion as a way to
build trust or “give control” to families with vaccine concerns, making
the HPV vaccine decision one that extends over multiple visits. Some
providers described wanting to avoid “a strong arm approach to vacci-
nating” and implied theywould prefer tomaintain a long-term, trusting
relationship with families than potentially lose that relationship be-
cause of a disagreement about HPV vaccine.
Table 2
Illustrative quotes, Minnesota (2012) and Washington (2015), USA.
Theme or subtheme Illustrative quote (study source)
Providers described a gradient of on-time HPV vaccination
ranging from age 12 to age 26.
[I worry about completion] Obviously when they start to get into their 20’s and they're approaching the end
of when it's recommended, although you're supposed to be able to ﬁnish it anytime, I think. (Washington)
When you use the term “catch up”, it's kind of interesting. With other vaccines, people get all kind of
freaked out. They're like, “Oh, I′m behind. I need to catch up.” But we don't use those terms for HPV.
Nobody's ever behind. Nobody needs to “catch up” HPV vaccination. (Minnesota)
[I start to worry] usually about 18. If we haven't gotten them in to get it all by the time they're 18, that's
usually when I start worrying about that it's going to be really difﬁcult, that's where there's fall off.
(Washington)
I delay pretty much everybody. To me it's not a problem. (Washington)
You're never really off time for HPV vaccine. (Minnesota)
I don't think I have [worried about completion] yet. I actually feel like most are eventually getting it.
(Washington)
Providers reﬁned their recommendations based on their
perceptions of patients' access to care and sexual risk
[I worry] As they get ready to head off to college, it's just harder for them to - they're not around as much so
they're less likely to get them all or to remember to do it during a winter break or something. (Washington)
[When recommending HPV vaccine] I say [sic] it's easier to do it when they're here at home before they go
away to school. (Minnesota)
[I think the time is really “now” for HPV vaccination] before college. We usually talk about it. People come in
9th grade or 10th grade, their sports physical runs out and they need another one so I know I′ll see them
again. Some 21, 22 year olds [come in unvaccinated] so we still bring it up. (Minnesota)
I would go into it a little more deeply and stress the need for the vaccine a little more if I knew the patient
was sexually active. (Minnesota)
I [worry] probably around 17 or 18, I start to say - or if they're sexually active, I'm like hey, there's still a 1 in
3 chance you could not have this. By around junior year of high school, I'm like c'mon, we gotta get this
going before you leave high school. (Washington)
I'm not dealing with a patient population whose sexual debut is likely to be very early. If I was with a
population where I was concerned that kids were having sex at age 12, I would be more aggressive.
(Washington)
Providers perceived that a “gentler” recommendation honors
parent preferences and builds long-term trust.
And give them permission [to delay], I think they like that. You can say “I think this is a good idea.” But then
I also say something like “If you feel like you're not ready to do it today, that's okay and we'll continue to
talk about it.” (Minnesota)
I let them know that I am here as a sounding board for them and help them sift through all that information.
I do not take a strong arm approach to vaccinating…[a colleague] was particularly militant about
vaccinating and I found that really turned off a lot of families, and I would rather have them come in and
have the discussion than not have them come in at all because they're worried they're going to get raked
over the coals. (Washington)
I'm more ﬂexible about “let's get this started sometime in the next couple years.” Let the parent feel they
have some control, which is I think what the whole issue is about with regard to vaccine hesitancy.
(Washington)
I don't pressure them. Let them make up their minds. (Minnesota)
[I′ll say] it's ﬁne if they want to wait and talk about it more. We'll just bring it up at the next visit.
(Minnesota)
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In this secondary comparative analysis of qualitative data from
healthcare providers in two samples, we found that a high proportion
of providers reported either a lack of concern about HPV vaccine com-
pletion or concern beginning several years past the CDC's recom-
mended target age. Our ﬁndings are consistent with other work
suggesting that providers may ﬁnd practice guidelines ambiguous. In
one study, a third of physicians said guidelines were unclear, and this
perception was associated with lower intention to recommend HPV
vaccine to girls (Kulczycki et al., 2015). Another study found that 45%
of providers found national or local guidelines for HPV vaccine are un-
clear (Bruno et al., 2014). The present exploratory study further extends
the current literature with its focus on providers' attitudes about thetimeliness of series completion. This is particularly important as one-
third of those who have received at least 1 dose of HPV vaccine do not
complete the series (CDC, 2015).
Healthcare provider recommendation of HPV vaccine is the stron-
gest, most consistent inﬂuence on parents' decisions about HPV vacci-
nation for their adolescent children (Dorell et al., 2012; Kessels et al.,
2012; Reiter et al., 2013b). Previous research highlights constructs im-
portant to a high-quality recommendation including: timeliness
(recommending by age 11–12), consistency (avoiding a risk-based ap-
proach), urgency (same day immunization) and strength of endorse-
ment (saying the vaccine is important) (Gilkey et al., 2015). The
present study provides insights into providers' perceptions and prac-
tices related to these constructs. We found evidence for a notable lack
of concern for “timeliness” in recommending the vaccine at target age.
97N.B. Henrikson et al. / Preventive Medicine Reports 4 (2016) 94–97This perspective offers a striking contrast to providers' perceptions of
early childhood vaccinations, where the use of catch-up schedules are
considered inferior to “on time” vaccination. Additional research is
needed to develop messages that better communicate to providers the
rationale behind and health beneﬁts of “on time” HPV vaccination by
age 12.
Optimal HPV vaccine recommendations should be universal at the
targeted age, not risk-based, to complete vaccination before sexual
debut (Dempsey, 2008). Providers in our study reported urgency
about recommending HPV vaccination on suspected patient sexual ac-
tivity, consistent with other research (Perkins et al., 2014; Gilkey and
McRee, 2016a). However, we also found that providers may gradually
increase the strength of their recommendations as their patients are
aging out of pediatric care or at risk of inconsistently accessing health
services as they transition out of high school. This concern about access
to care is not without empirical basis, as young adults have lower levels
of health service use than adolescents (Park et al., 2014). Future inter-
ventions should explore messaging that motivates providers to recom-
mend HPV vaccination well before anticipated care transitions.
Someproviders reported offering “gentler” recommendations byde-
ferring or readily accepting delay. This is a reasonable position for a pro-
vider who sees age 26 as timely vaccination, but parents may prefer
clear, unambiguous messages that HPV vaccination is important
(Gilkey and McRee, 2016b). Research in early childhood vaccine hesi-
tancy suggests that trust-based interventions may be insufﬁcient to
change parental vaccine attitudes(Henrikson et al., 2015a; Henrikson
et al., 2015b) and that strong recommendationsmay be effective for im-
proving vaccine coverage in the short term (Opel et al., 2016). Thus,
softer or deferred HPV vaccine recommendations may actually under-
mine vaccine recommendations. Future interventions can explore the
impact of different recommendation styles, HPV vaccination behavior,
and long-term trust.
Strengths of this study include the use of analytic triangulation to
compare ﬁndings across two independent samples of primary care pro-
viders; the high degree of convergence we found across geographic re-
gions and practice settings increases the credibility and transferability of
our ﬁndings. Limitations include the focused nature of our study, in
which we searched for evidence around a construct — physicians' con-
ceptualization of HPV vaccination timeliness. The sample size, while
small, was consistent with the exploratory, qualitative nature of our
study. These ﬁndings may not be generalizable to settings outside the
U.S. or to all U.S. health care settings or providers. We acknowledge also
that the multifactorial nature of provider communication style, parent
preferences, and clinical policies are also important for understanding
providers' ability to effectively deliver HPV vaccine recommendations.
5. Conclusion
Coverage of HPV vaccine continues to fall well below the national
goal of 80% (U.S. Department of Health and Human Services, 2013).
Our study identiﬁes ways that providers deviate from practice guide-
lines, suggesting that few health care providers prioritized the goal of
HPV vaccine series completion for patients by age 12. Further, many
providers appear to interpret on-time completion as age 26, not as 11
to 12 with an accompanying catchup schedule as is recommended. It
is logical, then, that they would only feel a sense of urgency as their pa-
tients approach their 20s, as suggested in this study. If conﬁrmed with
otherwork, future provider communication interventions could include
stressing age of 11 to 12 for on-time HPV vaccine completion. Interven-
tions that seek to change the cultural norm to one where “catch-up”
schedules are seen as suboptimal may offer particular promise. Given
the importance of the CDC-recommended vaccine schedules in the
United States, the intent behind the recommendation should be clearly
communicated and not left to individual interpretation.Transparency document
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